BriaCell Therapeutics Announces $8.5M Best-Efforts Offering Of 12.325M Common Shares At A Price Of $0.69/Share
BriaCell Therapeutics Announces $8.5M Best-Efforts Offering Of 12.325M Common Shares At A Price Of $0.69/Share
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 12,325,000 common shares (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof), priced at-the-market under Nasdaq rules. Each common share (or Pre-Funded Warrant) is being sold at an offering price of $0.69 per share (inclusive of the Pre-Funded Warrant exercise price). All of the common shares and Pre-Funded Warrants in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $8.5 million. The offering is expected to close on September 12, 2024, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
BriaCell Therapeutics Corp.（納斯達克股票代碼：BCTX，BCTXW）））（多倫多證券交易所股票代碼：BCT）（「BriaCell」 或 「公司」）是一家開發新型免疫療法以改變癌症治療的臨床階段生物技術公司，今天宣佈將盡最大努力發行12,325,000股普通股（或預融資認股權證（「預融資認股權證」）作爲代替發行12,32.5萬股普通股（或預籌認股權證（「預融資認股權證」）的定價其中），根據納斯達克規則在市場上定價。每股普通股（或預融資認股權證）將以每股0.69美元的發行價出售（包括預先注資的認股權證行使價）。本次發行中的所有普通股和預先注資的認股權證均由公司發行。在扣除配售代理費用和其他發行費用之前，此次發行的總收益預計約爲850萬美元。此次發行預計將於2024年9月12日結束，但須滿足慣例成交條件。該公司依賴《多倫多證券交易所公司手冊》第602.1條中規定的豁免，該條款規定，多倫多證券交易所不會將其標準適用於涉及納斯達克等認可交易所合格上市發行人的某些交易。
The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.
公司打算將本次發行的淨收益用於營運資金需求、一般公司用途和推進業務目標。
ThinkEquity is acting as sole placement agent for the offering.
ThinkEquity是本次發行的唯一配售代理人。
譯文內容由第三人軟體翻譯。